Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Jennifer P. Morton

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5766-9141; OpenAlex author ID A5004126873. Sources: OpenAlex.

Their work

Papers
71 (first author 8, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
257
Papers, trials and grants by year

2011: 3 papers · 2012: 1 paper · 2013: 3 papers · 2014: 2 papers · 2015: 2 papers · 2016: 4 papers · 2017: 8 papers · 2018: 6 papers · 2019: 6 papers · 2020: 4 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 7 papers · 2025: 5 papers · 2026: 7 papers

Papers 50 of 71

  1. Engineered cyclic peptide targeting ITGA5 disrupts tumor-stroma interaction to overcome desmoplasia and resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.apsb.2025.10.022↗
  2. Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. Co-author DOI 10.1016/j.jcmgh.2026.101872↗
  3. HSP47 is a potential dual cell target and prognostic factor in pancreatic cancer. Co-author DOI 10.1038/s41388-026-03865-y↗
  4. βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08657-6↗
  5. Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. Co-author DOI 10.1158/1535-7163.mct-25-0970↗
  6. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  7. Pharmacological arginine deprivation renders pancreatic cancer cells susceptible to senolysis and inhibition of the integrated stress response Co-author DOI 10.64898/2026.08.03.740778↗
  8. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08917-z↗
  9. Tumour genotype shapes blood biomarker expression for use in pancreatic cancer detection and diagnosis Co-author DOI 10.1101/2025.08.15.670486↗
  10. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  11. Induction of macrophage efferocytosis in pancreatic cancer via PI3Kγ inhibition and radiotherapy promotes tumour control. Co-author DOI 10.1136/gutjnl-2024-333492↗
  12. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Co-author DOI 10.1158/0008-5472.can-23-2709↗
  13. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Co-author DOI 10.1038/s41467-024-47949-3↗
  14. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00731-2↗
  15. Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00751-y↗
  16. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Co-author DOI 10.1126/sciadv.adl1197↗
  17. Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Last author DOI 10.1242/dmm.050463↗
  18. The preclinical gap in pancreatic cancer and radiotherapy. First author DOI 10.1242/dmm.050703↗
  19. Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. Co-author DOI 10.7554/elife.92672↗
  20. NUAK1 governs centrosome replication in pancreatic cancer via MYPT1/PP1β and GSK3β-dependent regulation of PLK4. Co-author DOI 10.1002/1878-0261.13425↗
  21. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Co-author DOI 10.1016/j.xcrm.2023.101007↗
  22. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinom… Co-author DOI 10.1136/jitc-2022-006457↗
  23. A microenvironment-inspired synthetic three-dimensional model for pancreatic ductal adenocarcinoma organoids. Co-author DOI 10.1038/s41563-021-01085-1↗
  24. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  25. βIII-Tubulin is a Brake on Extrinsic Cell-Death in Pancreatic Cancer Co-author DOI 10.1101/2022.09.29.510034↗
  26. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Co-author DOI 10.1136/gutjnl-2021-325272↗
  27. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  28. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Co-author DOI 10.1038/s41467-021-23731-7↗
  29. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  30. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  31. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Co-author DOI 10.1158/0008-5472.can-20-2496↗
  32. Heterogeneity in Pancreatic Cancer Fibroblasts-TGFβ as a Master Regulator? First author DOI 10.3390/cancers13194984↗
  33. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Co-author DOI 10.1016/j.clon.2019.08.007↗
  34. Asymmetrically Substituted Quadruplex-Binding Naphthalene Diimide Showing Potent Activity in Pancreatic Cancer Models. Co-author DOI 10.1021/acsmedchemlett.0c00317↗
  35. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-19-0620↗
  36. Environment Influences Tumor Progression and Transcriptional Subtype in a New Model of Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-20-1090↗
  37. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  38. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. Co-author DOI 10.1016/j.celrep.2019.09.056↗
  39. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  40. CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. Co-author DOI 10.1016/j.trecan.2019.09.010↗
  41. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Co-author DOI 10.1136/gutjnl-2018-316822↗
  42. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗
  43. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2018.05.038↗
  44. Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule. Co-author DOI 10.1021/acs.jmedchem.7b01781↗
  45. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. First author DOI 10.1038/s41419-018-0628-4↗
  46. Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2017.11.280↗
  47. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2017-315144↗
  48. Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci.insight.97422↗
  49. PTEN deficiency permits the formation of pancreatic cancer in the absence of autophagy. Co-author DOI 10.1038/cdd.2016.120↗
  50. SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Co-author DOI 10.1038/onc.2017.63↗

Closest collaborators

The 25 strongest of 257 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Owen James Sansom · 29 shared papers, 2011–2025 · strength 2.29
  2. Paul Timpson · 12 shared papers, 2011–2026 · strength 0.94
  3. Mathias Tesson · 3 shared papers, 2024–2025 · strength 0.89
  4. Anthony James Gill · 7 shared papers, 2018–2026 · strength 0.85
  5. Andrew Victor Biankin · 11 shared papers, 2014–2022 · strength 0.78
  6. David Kuang-Fu Chang · 9 shared papers, 2014–2025 · strength 0.77
  7. Marina Pajic · 8 shared papers, 2017–2026 · strength 0.73
  8. Amber L. Johns · 6 shared papers, 2018–2026 · strength 0.72
  9. Valeria Quaranta · 4 shared papers, 2022–2024 · strength 0.64
  10. Yuliana Astuti · 4 shared papers, 2022–2024 · strength 0.64
  11. Paula Ghaneh · 4 shared papers, 2022–2024 · strength 0.64
  12. Michael C. Schmid · 4 shared papers, 2022–2024 · strength 0.64
  13. Ainhoa Mielgo · 4 shared papers, 2022–2024 · strength 0.64
  14. Daniel H. Palmer · 4 shared papers, 2022–2024 · strength 0.64
  15. Meirion Raymant · 4 shared papers, 2022–2024 · strength 0.64
  16. Gaia Bellomo · 4 shared papers, 2022–2024 · strength 0.64
  17. Christopher Michael Halloran · 4 shared papers, 2022–2024 · strength 0.64
  18. Keaton Ian Jones · 3 shared papers, 2024–2025 · strength 0.62
  19. David Goldstein · 4 shared papers, 2021–2026 · strength 0.59
  20. Val Gebski · 4 shared papers, 2021–2026 · strength 0.59
  21. Joshua A. McCarroll · 4 shared papers, 2021–2026 · strength 0.59
  22. Mert Erkan · 4 shared papers, 2021–2026 · strength 0.59
  23. Koroush Shahsavar Haghighi · 4 shared papers, 2021–2026 · strength 0.59
  24. Phoebe A. Phillips · 4 shared papers, 2021–2026 · strength 0.59
  25. George Sharbeen · 4 shared papers, 2021–2026 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.